Hyundai ADM Bio (CEO Taek-Seong Kim and Gwang-Hee Kim) announced on the 14th that it will present the preclinical results of the cancer treatment efficacy of OTX-M, an oral docetaxel/paclitaxel formulation, at 'Biotech Showcase 2025' to be held in San Francisco, USA from the 13th to the 15th.
OTX-M is an oral anticancer drug that uses ‘oral drug delivery platform technology’ to improve the bioavailability of docetaxel and paclitaxel, representative chemotherapeutic anticancer drugs that were previously administered only as injections due to the problem of low bioavailability of the drugs, by more than 1,600 times.
Preclinical results of the cancer treatment efficacy trial confirmed that OTX-M's 'metronomic chemotherapy' (chemotherapy in which small doses are taken daily without a break) minimized side effects and maximized anticancer effects.
◆ Metronomic chemotherapy with oral anticancer drugs, overcoming the limitations of existing injection-based chemotherapy
Existing injectable anticancer drugs require a break between hospital visits and treatments, which reduces the continuity of cancer management, significantly reduces the quality of life of patients due to severe side effects from high-dose administration, and places a huge burden on the medical system.
Metronomic chemotherapy, which involves taking small doses of OTX-M daily without a break, is expected to become a new standard for chemotherapy as it significantly reduces the toxicity and side effects caused by high-dose administration of existing injectable drugs, improves the quality of life of patients, and continuously maintains blood drug concentrations to maximize the cancer cell suppression effect. In addition, it allows cancer patients to manage their cancer at home while maintaining their daily lives without visiting the hospital.
Kim Taek-seong, CEO of Hyundai ADM, said, “OTX-M will be a turning point that opens an era in which cancer patients can manage their cancer on their own, just like hypertension or diabetes.” He added, “Metronomic chemotherapy without a break is a treatment method that can reduce the pain of cancer patients while maximizing the treatment effect. We hope that this study, which has realized this as an oral anticancer drug, will suggest a new direction for cancer treatment.”
The results of this research will be announced directly by Hyundai ADM CEO Taek-Sung Kim at 10:00 AM (local time) on the 14th.
- See more related articles
You must be logged in to post a comment.